Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy

Blood

Volumn 100, Issue 4, 2002, Pages 1168-1171

  Zangari, Maurizio ^a,b,c   Siegel, Eric ^a,b   Barlogie, Bart ^a,b   Anaissie, Elias ^a,b   Saghafifar, Fariba ^a,b   Fassas, Athanasios ^a,b   Morris, Christopher ^a,b   Fink, Louis ^a,b   Tricot, Guido ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; THALIDOMIDE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PHLEBOGRAPHY; PRIORITY JOURNAL; RELAPSE; THROMBOGENICITY;

EID: 0037103292     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0335     Document Type: Article

References (23)

1. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
2. Total therapy with tandem transplants for newly diagnosed multiple myeloma
3. The influence of immunoglobulin (IgG) on the assembly of fibrin gels
4. Inhibition of conversion of fibrinogen to fibrin by abnormal proteins in multiple myeloma
5. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma
6. Light chain paraproteins with lupus anticoagulant activity
7. Study of three patients with monoclonal gammopathies and lupus-like anticoagulants
8. Time course of hemostastic abnormalities in sepsis and its relation to outcome
9. Antitumor activity of thalidomide in refractory multiple myeloma
10. Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: Identification of prognostic factors in a phase II study of 169 patients
11. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
12. Deep vein thrombosis and thalidomide therapy for multiple myeloma
13. Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM)
14. Use of ranks in one-criterion analysis of variance
15. Nonparametric estimation from incomplete observations
16. Regression models and life tables (with discussion)
17. 2 tests
18. Statistical aspects of the analysis of data from retrospective studies of disease
19. A phase II trial of weekly intravenous gemcitabine (G) with prolonged continuous infusion 5-fluorouracil (F) and oral thalidomide (T) in patients with metastatic renal cell cancer
20. Phase II trial of thalidomide and BCNU in recurrent high-grade gliomas
21. Dose finding study of cisplatin, gemcitabine and SU5416 in patients with advanced malignancies
22. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer